SOSAFE
24.5.2023 08:01:30 CEST | Business Wire | Press release
SoSafe, Europe’s leading vendor for security awareness and training, today announced it has appointed two world-class cybersecurity industry leaders to its board: Tech executive Zeynep Inanoglu Ozdemir, former CMO at Palo Alto Networks, and Bhagwat Swaroop, experienced executive in the cybersecurity space and current President of Digital Security Solutions at Entrust.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005033/en/
Europe’s leading security awareness and training vendor SoSafe adds Zeynep Inanoglu Ozdemir, former CMO at Palo Alto Networks, to their board. (Photo: Business Wire)
Niklas Hellemann, CEO of SoSafe: “At SoSafe, we are at the forefront of security awareness innovation. Bringing two world-class industry leaders like Zeynep and Bhagwat for our board will strengthen our market expertise even further, boosting international expansion and product excellence. Advances in generative AI will inevitably lead to an escalation of the cyber threat landscape, particularly from a human risk perspective. We are delighted to welcome two highly experienced cybersecurity experts to our board, helping us to navigate this paradigm shift. SoSafe’s whole management team is very much looking forward to working with them.”
Zeynep Inanoglu Ozdemir has held key marketing leadership roles at Palo Alto Networks during a four-year period of rapid growth and transformation. As CMO, she has been responsible for launching an award-winning brand campaign for the company as well as pioneering the XDR category in cybersecurity at large. Previously, Ozdemir has worked at Palantir Technologies and Google, and currently sits on the board at iKSV, Turkey’s predominant arts and culture foundation. She holds a PhD in speech processing from Cambridge University, Machine Intelligence Lab, and a bachelor's degree in electrical engineering from Harvard University. Her deep expertise in category creation, data-driven marketing and growth strategies will be of great value to our board at SoSafe.
“Human-level risk management and security awareness programs are key capabilities in an increasingly automated threat landscape”, says Ozdemir. “I am very excited work with SoSafe to further their mission to drive secure behavior at scale.”
Bhagwat Swaroop is the President of Digital Security Solutions at Entrust and brings more than 20 years of leadership experience driving growth in global high-tech companies to the board. He was most recently president and General Manager of One Identity, where he led the company’s turnaround to a cloud-based cybersecurity company. Prior to One Identity, Swaroop was a Corporate Officer and Executive Vice President at Proofpoint responsible for driving company’s rapid growth and helped make Proofpoint the market leader in email security. Previously he held leadership positions at Symantec, NetApp, McKinsey, and Intel. He is a seasoned strategic leader and brings a deep understanding of the enterprise security landscape, technology ecosystem and cloud driven business models. He is a sought expert and public speaker on cybersecurity, cloud computing and national policy topics. “Security awareness training has become a foundational capability to make the human layer more resilient to the constant phishing attempts.” states Swaroop. “I was impressed by SoSafe’s deep focus on fusing behavioral science with cybersecurity awareness solutions. I am looking forward to working with the SoSafe leadership team in the next phase of their growth journey”.
With these new additions to its board, European security awareness leader SoSafe underlines its commitment for international expansion and product innovation.
_______________
About SoSafe
SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by Dr Niklas Hellemann, Lukas Schaefer, and Felix Schuerholz. Today, it serves more than 3000 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team consists of more than 370 employees at five locations: Cologne (headquarters), Amsterdam, Berlin, London, and Paris.
Website: www.sosafe-awareness.com/
LinkedIn: https://www.linkedin.com/company/sosafe-cyber-security/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005033/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
